____________________________________
EVENTS
___________________________________
MAR. 31 & APR. 1
BIO LEGISLATIVE DAY FLY-IN
Four Points Sheraton
1201 K Street, NW
Washington, D.C.
____________________________________
APR. 9
INNOVATIVE TECHNOLOGIES BREAKFASTS
7:30 a.m. to 9:00 a.m.
_______________________
APR. 29
DELAWARE BIO ANNUAL AWARDS GALA
DuPONT COUNTRY CLUB
5:30 p.m. - 10:00 p.m.
___________________________
MAY 13 - 15
Loews Philadelphia
Hotel
Philadelphia, PA
___________________________
MAY 18 - 21
BIO 2009
Atlanta Convention
Center
Atlanta, GA
____________________________
JUNE 9 & 10
EARLY STAGE EAST
Applications close
April 24.
Hotel DuPont
Wilmington, DE
______________________________
Walter E. Washington
Convention Center
Washington, D.C.
____________________________________
SAVE THESE DATES!
2009 Upcoming BioBreakfasts
WEDNESDAY, MAY 13
Delaware Biotechnology Institute
15 Innovation Way, Newark, DE.
7:30 a.m. - 9:00 a.m. |
TUESDAY, JULY 14
John H. Ammon Medical Education Center
Christiana Care
Newark, DE
7:30 a.m. - 9:00 a.m.
|
|
|
|
 |
BIOTECHNOLOGY INDUSTRY
EXPECTED TO REBOUND
|
According to BIO/Thomson Reuters Investor Perception Study released in February at the 11th Annual BIO CEO & Investor Conference in New York, the biotechnology industry is expected to rebound and outperform healthcare and the rest of the market this year.
The perception study is an in-depth assessment of Wall Street's views of the biotech industry, its current challenges, its relative valuation, and the outlook for 2009. The purpose of the study is to inform and improve communication between biotech executives, investors and policymakers.
According to participants, who represent firms with $2.3 trillion in assets under management, the credit crisis has shifted investors' focus with over 80% acknowledging that the effects have forced them to change their investment approaches. In particular, they have stated that a company's cash position is now more important. More than two-thirds in the study expect greater M&A volume in 2009, with major pharmaceutical companies buying biotech of all sizes and large biotechs buying smaller biotech companies.
In addition, the study found that most investors are neutral to positive about the policies likely to be pursued by the Obama administration. Investors are particularly hoping for greater consistency and predictability from the FDA where higher safety barriers and insufficient resources are cited as primary reasons for limited drug approvals.
Most investors pay little attention to activism in the biotech sector, according to the study. Looking at what the 'smart money owns' is the least popular source of new investment ideas and least important for research. Meeting with management is the most important factor when researching investments, followed by conferences and sell-side research, which is still considered important.
The perception study was conducted by Thomson Reuters, in conjunction with BIO's Investor Relations team, during December and January. It included over 80 participants representing firms with $2.3 trillion in assets under management and included $266 billion in healthcare and $76 billion in biotech.
The full study will be released at the end of March.
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization.
Bio represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
|
|
|
|
|
